COL7A1 and recessive dystrophic epidermolysis bullosa: Using a herpes simplex virus‐based vector B‐VEC delivers functional COL7A1 genes, restoring C7 production in vivo[5] On the other hand, cell therapies promise long‐term improvement of the RDEB disease phenotype.